For ovarian cancer, immunotherapy holds considerable potential, encompassing strategies such as immune checkpoint inhibitors (2–4) (e.g., anti-PD-1/PD-L1 and anti-CTLA-4 antibodies), chimeric antigen receptor (5) (CAR) T-cell therapies, cancer vaccines (6, 7), and oncolytic virotherapy (8). This evidence concerns the gene RPL17 and ovarian carcinoma.